Genetically Targeted Therapy for the Prevention of Symptomatic Atrial Fibrillation in Patients With Heart Failure

Completed · Phase 2 · Has a placebo group

Conditions studied: Current or Recent History of Atrial Fibrillation

In brief

This study is being done to compare the effects of bucindolol hydrochloride (bucindolol) to metoprolol succinate (Toprol-XL) on the recurrence of symptomatic atrial fibrillation/atrial flutter in patients with heart failure who have a specific genotype for the beta-1 adrenergic receptor.

Key facts

Study ID
NCT01970501
Run by
ARCA Biopharma, Inc.
People needed
267
Starts
2014-04-01
Expected to finish
2017-12-28
Last updated by the study team
2022-09-26

Who can join

Age: 18 and older, up to 85. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.